Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter Clayton is active.

Publication


Featured researches published by Peter Clayton.


American Journal of Human Genetics | 2000

Mutational Spectrum in the Δ7-Sterol Reductase Gene and Genotype-Phenotype Correlation in 84 Patients with Smith-Lemli-Opitz Syndrome

M. Witsch-Baumgartner; B.U. Fitzky; M. Ogorelkova; H.G. Kraft; F.F. Moebius; H. Glossmann; U. Seedorf; G. Gillessen-Kaesbach; Georg F. Hoffmann; Peter Clayton; Richard I. Kelley; Gerd Utermann

Smith-Lemli-Opitz syndrome (SLOS), an autosomal recessive malformation syndrome, ranges in clinical severity from mild dysmorphism and moderate mental retardation to severe congenital malformation and intrauterine lethality. Mutations in the gene for Δ7-sterol reductase (DHCR7), which catalyzes the final step in cholesterol biosynthesis in the endoplasmic reticulum (ER), cause SLOS. We have determined, in 84 patients with clinically and biochemically characterized SLOS (detection rate 96%), the mutational spectrum in the DHCR7 gene. Forty different SLOS mutations, some frequent, were identified. On the basis of mutation type and expression studies in the HEK293-derived cell line tsA-201, we grouped mutations into four classes: nonsense and splice-site mutations resulting in putative null alleles, missense mutations in the transmembrane domains (TM), mutations in the 4th cytoplasmic loop (4L), and mutations in the C-terminal ER domain (CT). All but one of the tested missense mutations reduced protein stability. Concentrations of the cholesterol precursor 7-dehydrocholesterol and clinical severity scores correlated with mutation classes. The mildest clinical phenotypes were associated with TM and CT mutations, and the most severe types were associated with 0 and 4L mutations. Most homozygotes for null alleles had severe SLOS; one patient had a moderate phenotype. Homozygosity for 0 mutations in DHCR7 appears compatible with life, suggesting that cholesterol may be synthesized in the absence of this enzyme or that exogenous sources of cholesterol can be used.


42nd Meeting of the British Society for Paediatric Endocrinology and Diabetes | 2014

Impaired insulin and IGF2 signalling in the primordial growth disorder 3-M syndrome

Jins Kallampallil; Ksenija Acimovic; Daniel Hanson; Andrew Whatmore; Peter Clayton

 Relative phosphorylation of AKT was assessed by western blotting and comparisons made both within and between cell lines. In view of this altered growth factor signalling, we have investigated the activation of AKT by IGF-2 and Insulin.  Relative pAKT was reduced in 3-M fibroblasts compared to normal cells when stimulated with either insulin (p = 0.048) or IGF-2 (p = 0.033) (Fig. 2).  For both treatments, CUL7-/and OBSL1-/cells had a markedly lower activation of pAKT than did CCDC8-/cells.  CUL7-/cells had an earlier activation in response to insulin (p = 0.016) than other cell types.


American Journal of Human Genetics | 2013

Next-Generation Sequencing Reveals Deep Intronic Cryptic ABCC8 and HADH Splicing Founder Mutations Causing Hyperinsulinism by Pseudoexon Activation

Sarah E. Flanagan; Weijia Xie; Richard Caswell; Annet Damhuis; Christine Vianey-Saban; Teoman Akcay; Feyza Darendeliler; Firdevs Bas; Ayla Güven; Zeynep Siklar; Gönül Öcal; Merih Berberoglu; Nuala Murphy; Maureen J. O'Sullivan; Andrew Green; Peter Clayton; Indraneel Banerjee; Khalid Hussain; Michael N. Weedon; Sian Ellard


Endocrine Abstracts | 2018

Gene expression signatures in children with growth hormone deficiency (GHD) and Turner syndrome (TS) predict response to growth hormone

Peter Clayton; Adam Stevens; Philip Murray; Terence Garner


Endocrine Abstracts | 2018

Optimising diagnostic performance of IGF-I and IGFBP-3 measurement: importance of reference range and cut-off value

Laila Al-Hashmi; Claire Manfredonia; Indi Banerjee; Lesley Tetlow; Philip Murray; Peter Clayton


45th Meeting of the British Society for Paediatric Endocrinology and Diabetes | 2017

Impact of risk factors for Fetal Growth Restriction (FGR) on intrauterine growth and birthweight

Reena Perchard; Lucy Higgins; Edward Johnstone; Peter Clayton


Archive | 2016

Genetic Insights from Children with Idiopathic Short Stature in the EPIGROW Study

Reena Perchard; Philip Murray; Anthony Payton; Peter Clayton


Archive | 2016

Transcriptomics and Machine Learning Methods Accurately Predict Diagnosis and Severity of Childhood Growth Hormone Deficiency

Philip Murray; Adam Stevens; Ekaterina Koledova; Pierre Chatelain; Peter Clayton


55th Annual ESPE | 2016

In vitro and in vivo Evidence for a Growth Inhibitory Role of the Transcription Factor ZBTB38 Throughout Pre- and Post-Natal Life

Sam Parsons; Adam Stevens; Andrew Whatmore; Philip Murray; Peter Clayton


Archive | 2015

The In vitro Functional Analysis of Gene Promoter Region Single Nucleotide Polymorphisms Associated with GH Response in Children with GH Deficiency

Leonibus Chiara De; Philip Murray; Dan Hanson; Adam Stevens; Peter Clayton

Collaboration


Dive into the Peter Clayton's collaboration.

Top Co-Authors

Avatar

Philip Murray

Manchester Academic Health Science Centre

View shared research outputs
Top Co-Authors

Avatar

Adam Stevens

University of Manchester

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mars Skae

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

Raja Padidela

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Sarah Ehtisham

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Indi Banerjee

University of Manchester

View shared research outputs
Top Co-Authors

Avatar

Lindsey Rigby

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge